Literature DB >> 29084639

Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.

Inês Raposo1, Cláudia Carvalho2, Andreia Bettencourt2, Berta Martins Da Silva2, Luiz Leite3, Manuela Selores4, Tiago Torres4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29084639     DOI： 10.1684/ejd.2017.3071

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  4 in total

1.  Variants in PRKCE and KLC1, Potential Regulators of Type I Psoriasis.

Authors:  Jianxiao Xing; Ying Wang; Xincheng Zhao; Junqin Li; Ruixia Hou; Xuping Niu; Guohua Yin; Xinhua Li; Kaiming Zhang
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-01

2.  Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.

Authors:  Marina Talamonti; Marco Galluzzo
Journal:  Ann Transl Med       Date:  2020-08

Review 3.  Pharmacogenetics Update on Biologic Therapy in Psoriasis.

Authors:  Ester Muñoz-Aceituno; Luisa Martos-Cabrera; María Carmen Ovejero-Benito; Alejandra Reolid; Francisco Abad-Santos; Esteban Daudén
Journal:  Medicina (Kaunas)       Date:  2020-12-20       Impact factor: 2.430

Review 4.  Towards Personalized Medicine in Psoriasis: Current Progress.

Authors:  Elisa Camela; Luca Potestio; Angelo Ruggiero; Sonia Sofia Ocampo-Garza; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.